Monica Noether

Senior Consultant

Dr. Noether specializes in antitrust analysis and other competitive issues related to the healthcare industry for law firms, professional associations, government agencies, and other clients.

She has analyzed dozens of hospital, health plan, provider, and medical supplier mergers as well as competitive disputes between different players in the healthcare sector. She is also an expert in public and private-sector provider reimbursement policies. She has provided expert testimony in antitrust and reimbursement litigation, analyzing class certification, merits, and damages questions. While she is best known for her work in the healthcare industry, she also has broad general expertise in all aspects of antitrust analyses. She has also worked on matters involving insurance, pharmaceuticals, software, retailing, wholesale, distribution, music, soft drinks, and energy.

Dr. Noether has also served in several senior leadership positions at CRA, including as Chief Operating Officer from 2009 to 2012. Prior to joining CRA 28 years ago, Dr. Noether served as a managing vice president at a government and business research and consulting company, where she specialized in federal reimbursement policy of healthcare providers and in antitrust issues. She also spent several years at the Federal Trade Commission as a deputy assistant director in the Bureau of Economics and Commissioner Advisor.

Selected engagements

  • 01
    Strategic planning of STEM programming for Boston-area girls from grades K-8
    Through CRA’s partnership with Social Venture Partners Boston, Monica Noether has been working with Science Club For Girls, a Boston-area non-profit that...
    View engagement
  • 02
    Cigna-Anthem Merger Litigation
    CRA was retained by counsel for Cigna Corporation in a litigation in Delaware Chancery Court arising from its unsuccessful merger with Anthem, Inc. Both...
    View engagement
  • 03
    Fresenius acquisition of NxStage Medical, Inc.
    CRA consultants advised counsel to Fresenius Medical Care Holdings, Inc. and NxStage Medical, Inc. as they sought regulatory approval of Fresenius’ $2 billion...
    View engagement

Credentials